使用人口药理动力学建模和模拟进行暴露匹配,以支持对患有偏头痛的儿科患者的里米格潘特剂量选择
Craig M Comisar1, Jim H Hughes2, Gary Mo3
1Certara, Princeton, New Jersey, USA.
Clinical and translational science
|October 17, 2025
概括
这项研究确定了儿科偏头痛治疗的最佳rimegepant剂量. 推剂量因年龄和体重而异,以确保在儿童中安全有效地暴露于与素基因相关的受体对抗剂.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 儿科医学 儿科医学
背景情况:
- 里米杰邦 (Rimegepant) 是一种与素基因相关的受体对手,已被批准用于成人偏头痛治疗.
- 种群药动力学 (PopPK) 模型对于优化不同种群中的药物剂量至关重要.
- 之前的rimegepant的PopPK模型仅基于成人数据.
研究的目的:
- 更新rimegepant PopPK模型使用综合儿科和成人数据.
- 在虚拟儿科群体中模拟rimegepant暴露.
- 建议基于年龄和体重的rimegepant剂量用于儿科偏头痛治疗.
主要方法:
- 更新了以前开发的成人PopPK模型,其中包括一个儿科和两个成人研究的数据.
- 使用美国国家增长图表生成虚拟儿科人口.
- 对各种剂量和年龄/体重组 (6-17岁) 进行模拟的rimegepant暴露.
主要成果:
- 在儿科患者 (6-17岁) 中,根据年龄和体重确定了rimegepant的剂量建议.
- 推剂量从35毫克到75毫克不等,取决于年龄和体重.
- 针对儿童/成人暴露比接近1且小于或等于2的选择剂量.
结论:
- 更新的PopPK模型为儿科rimegepant剂量提供了基础.
- 推剂量支持进一步评估rimegepant在儿科偏头痛中的疗效和安全性.
- 这项研究有助于个性化医疗方法在儿科偏头痛管理.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
3.4K
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
3.1K
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
673
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
673
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
209
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
148
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
148
01:26Pharmacokinetic Models: Comparison and Selection Criterion
332
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
332
01:29Drug Dosing: Infants and Children
250
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
250
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
191
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
191